A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2013
Aiheet:
Phase I Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://ncbi.nlm.nih.gov/pubmed/23860641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0001-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia